1st Quarter - Report

AMERICAN OSTEOPATHIC ASSOCIATION for AMERICAN OSTEOPATHIC ASSOCIATION

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$205,761
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report (this page) Apr 20, 2017 $205,761 Replaced
1st Quarter - Amendment Apr 20, 2017 $205,761 Replaced
1st Quarter - Amendment Apr 20, 2017 $205,761 Yes

What was lobbied

9 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

Recognition of Osteopathic Certification

LobbyistCovered position, as disclosed
RYAN MCBRIDE Lobbyist
JOHN MICHAEL C. VILLARAMA Lobbyist
LAURA WOOSTER Sr. Vice President Public Policy

Contacted: Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Government Accountability Office (GAO); Agency for Healthcare Research & Quality (AHRQ); White House Office

Taxation/Internal Revenue Code TAX

Flexible Spending Accounts; Health Savings Accounts

LobbyistCovered position, as disclosed
RYAN MCBRIDE Lobbyist
JOHN MICHAEL C. VILLARAMA Lobbyist
LAURA WOOSTER Sr. Vice President Public Policy

Contacted: Centers For Disease Control & Prevention (CDC); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); White House Office; HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); SENATE; Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Government Accountability Office (GAO)

Insurance INS

Health Insurance; Professional Liability Insurance; State Insurance Marketplace

LobbyistCovered position, as disclosed
RYAN MCBRIDE Lobbyist
JOHN MICHAEL C. VILLARAMA Lobbyist
LAURA WOOSTER Sr. Vice President Public Policy

Contacted: White House Office; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); SENATE; Health Resources & Services Administration (HRSA); Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); Medicare Payment Advisory Commission (MedPAC)

Education EDU

Student Loan Financing and Re-Financing

LobbyistCovered position, as disclosed
RYAN MCBRIDE Lobbyist
JOHN MICHAEL C. VILLARAMA Lobbyist
LAURA WOOSTER Sr. Vice President Public Policy

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Government Accountability Office (GAO); Health Resources & Services Administration (HRSA); Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Medicare Payment Advisory Commission (MedPAC); Executive Office of the President (EOP); White House Office; SENATE; Office of Management & Budget (OMB); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA)

Budget/Appropriations BUD

Labor HHS Appropriations

LobbyistCovered position, as disclosed
RYAN MCBRIDE Lobbyist
JOHN MICHAEL C. VILLARAMA Lobbyist
LAURA WOOSTER Sr. Vice President Public Policy

Contacted: Government Accountability Office (GAO); Agency for Healthcare Research & Quality (AHRQ); SENATE; Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC); White House Office; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP)

Health Issues HCR

U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), White House Office, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), Office of Management & Budget (OMB), Executive Office of the President (EOP)

LobbyistCovered position, as disclosed
RYAN MCBRIDE Lobbyist
JOHN MICHAEL C. VILLARAMA Lobbyist
LAURA WOOSTER Sr. Vice President Public Policy

Contacted: White House Office; Government Accountability Office (GAO); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); SENATE; Office of Management & Budget (OMB); Medicare Payment Advisory Commission (MedPAC); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA)

Medicare/Medicaid MMM

Graduate Medical Education; Health Care Quality, Patient Access to Health Care; Physician Workforce; Medicare Physician Payment Issues; Independent Payment Advisory Board. H.R. 574, The Medicare Physician Payment Innovation Act of 2013.

LobbyistCovered position, as disclosed
RYAN MCBRIDE Lobbyist
JOHN MICHAEL C. VILLARAMA Lobbyist
LAURA WOOSTER Sr. Vice President Public Policy

Contacted: Centers For Disease Control & Prevention (CDC); Executive Office of the President (EOP); Medicare Payment Advisory Commission (MedPAC); Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); White House Office; Health Resources & Services Administration (HRSA); Office of Management & Budget (OMB); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 574 (115th)

Medical/Disease Research/Clinical Labs MED

NIH; FDA; Agency for Health Care Quality & Research Funding

LobbyistCovered position, as disclosed
RYAN MCBRIDE Lobbyist
JOHN MICHAEL C. VILLARAMA Lobbyist
LAURA WOOSTER Sr. Vice President Public Policy

Contacted: Health Resources & Services Administration (HRSA); Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC); Office of Management & Budget (OMB); Medicare Payment Advisory Commission (MedPAC); Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); White House Office; Government Accountability Office (GAO); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Torts TOR

Professional Liability Insurance; Medical Liability Reform

LobbyistCovered position, as disclosed
RYAN MCBRIDE Lobbyist
JOHN MICHAEL C. VILLARAMA Lobbyist
LAURA WOOSTER Sr. Vice President Public Policy

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); Office of Management & Budget (OMB); Agency for Healthcare Research & Quality (AHRQ); SENATE; White House Office; Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); Executive Office of the President (EOP); Centers For Disease Control & Prevention (CDC); Government Accountability Office (GAO); Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.